ALISO VIEJO, Calif.–(BUSINESS WIRE)–AqueSys, Inc., manufacturers of the XEN Gel Stent, is hosting a symposium at the World Glaucoma Congress June 7 in Hong Kong to present the benefits of the minimally invasive device in reducing IOP.
Author: Business Wire
FDA Clears NovaBay Pharmaceuticals’ New High-Tech Device, intelli-Case, for Safely Disinfecting Contact Lenses with Hydrogen Peroxide
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel approaches for the global eye care market, including revolutionary non-antibiotic antimicrobial products, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its novel intelli-Case with hydrogen peroxide solutions. Click here to view a presentation on intelli-Case. More than 24 million Americans n
Acucela Announces Publication of Phase 2a Clinical Trial Results for Emixustat Hydrochloride
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, to…
Ophthotech Corporation to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Goldman Sachs 36th Annual Global Healthcare Conference on June 10, 2015.
Second Sight Appoints Matthew J. Pfeffer to Its Board of Directors
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that provide functional vision to blind patients, today annou…
EYE TECH CARE在中國發展業務，成為其全球擴張的一部分
法國RILLIEUX-LA-PAPE–(BUSINESS WIRE)–(美國商業資訊) — EYE TECH CARE SA (ETC)是開發和行銷眼科無創治療醫療器材的公司，該公司今天宣佈，其用於治療青光眼的創新系統EyeOP1®已獲得中國食品藥品監督管理局(CFDA)的醫療器械分類，開始審核流程。 繼EyeOP1®在歐洲和美國（EYE TECH CARE的主要目標市場）上市之後，中國成為該公司的關鍵市場：中國青光眼患者有2200萬人，占全球青光眼病例人數的28% (MarketScope 2014)。這些患者中多數為晚期青光眼，需要手術治療，由於手術步驟和病情的複雜性，手術後可導致各種併發症，手術需要由受過專科訓練的外科醫師在專科治療機構中進行。 EyeOP1®是ETC開發的創新醫學解決方案，用於治療青光眼，可替代手術治療。它可用於所有青光眼未獲控制的患者，無論患者既往是否接受過治療，可完全符合中國市場的需求。該治療為門診手術，可顯著降低眼內壓。該手術的原理是對睫狀體進行超音波處理（即手術治療），使眼睛的這一部位產生精確定位的輕微凝固，從而減少水性體液的生成。對醫師而言，該
Ocular Therapeutix, Inc. Announces Proposed Public Offering of Common Stock
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. The offering consists of 3,200,000 shares being offered by the Compa…
Ocata Therapeutics Receives Important New U.S. Patent for its RPE Therapy for Macular Degenerative Diseases
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the scope of protection covering its retinal pigment epithelium (RPE) transplant technology with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,045,732. This new patent further strengthens the Company’s comprehensive suite of intellectual property which
EYE TECH CARE Launches Its Operations in China as Part of Its International Expansion
RILLIEUX-LA-PAPE, France–(BUSINESS WIRE)–EYE TECH CARE launches its operations in China as part of its international expansion.
EYE TECH CARE Launches Its Operations in China as Part of Its International Expansion
RILLIEUX-LA-PAPE, France–(BUSINESS WIRE)–EYE TECH CARE launches its operations in China as part of its international expansion.
Bruker Introduces MALDI Tissuetyper™ Solution with New High Speed rapifleX™ MALDI-TOF MS System for Anatomical Pathology Research
ST. LOUIS–(BUSINESS WIRE)–At the 63rd ASMS Conference on Mass Spectrometry & Allied Topics (ASMS), Bruker (NASDAQ: BRKR) announced the launch of the novel MALDI Tissuetyper solution, based on the new rapifleX MALDI-TOF Mass Spectrometry system. The introduction of the revolutionary rapifleX as the new instrument platform for MALDI imaging anatomical pathology research further enhances Bruker’s leadership position for MALDI-TOF-based applications solutions. The new rapifleX system eliminat
Bruker Introduces Comprehensive Mycobacteria Library 3.0 for High-Performance MALDI Biotyper Mycobacteria Identification
NEW ORLEANS–(BUSINESS WIRE)–At the 115th General Meeting of the American Society for Microbiology, Bruker (NASDAQ: BRKR) announced a major version 3.0 expansion of the proven Mycobacteria Library for research use only on the MALDI Biotyper microbial …
Tyrogenex X-82 Poster Presentation at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting
PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, a leader in the development of novel kinase inhibitors to target angiogenesis, announced that the University of Wisconsin presented a new trial concept of X-82 poster at ASCO in Chicago.
Second Sight to Present at Investor Conference on June 4, 2015
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today announced that the Company will present at the Three Part Advisors East Coast IDEAS Conference, as follows: Presentation Date: Thursday, June 4, 2015 Presentation Time: 3:10 p.m. EDT Location: Boston Park Plaza, Boston, MA The presentation will be we
Research and Markets: Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/mn2tbt/keratoconjunctivit) has announced the addition of the “Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2015” report to their offering. This repo…
Aerie Pharmaceuticals to Participate in Two Investor Conferences in June
IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present an overview of the company at the following conferences in
Doctors Embrace Avenova™ for Common Eye Conditions
SAN RAFAEL, Calif.–(BUSINESS WIRE)–The Eye Institute, located in Marin County, California, announced today that an informal survey of eye doctors shows a major surge in the use of Avenova, a lid & lash hygiene product that was developed by the Eye Institute and NovaBay Pharmaceuticals (NYSE MKT:NBY) for eye conditions that affect millions of Americans. In addition, an increasing number of those doctors are writing articles describing why Avenova has been so beneficial to patients. “When w
豪雅集团旗下宾得医疗上市用于胃癌早期治疗的 新款多功能内镜粘膜下层剥离器械高频切开刀(Splash M-Knife)
东京–(BUSINESS WIRE)–(美国商业资讯)–豪雅集团旗下宾得医疗上市新款多功能内镜黏膜下剥离器械高频切开刀 (Splash M-Knife)，以实现通过单件器械完成完全性内镜黏膜下剥离术（以下简称ESD）。该新款器械将在日本消化器内视镜学会 (JGES) 第89届年会上展示，该年会将于2015年5月29至31日在日本名古屋召开。 开发可弯曲内窥镜旨在与其他治疗器械一起用于各类微创治疗手术。ESD是十多年前日本发明的一种手术，由于其具有临床和经济效益，有助于早期恢复、降低复杂性和成本，因而已在世界各地普及。 全球产品管理副总裁Rami Liebenthal做出如下评论：“我们正在上市高频切开刀，这是一种创新的多功能ESD器械，它有助于ESD的全球普及，加快胃癌的早期治疗。我们相信，用于精确、高效、更安全ESD的创新器械为开展完全性ESD治疗设立了一个新标准。我们致力于推广该手术及其进一步的开发。” 宾得医疗的高频切开刀具有下列特点。 多功能它可实现清晰的标记、更好的止血、更顺利更轻松的手术，手术过程中无需替换刀具。 独特的机制刀具中的盘片可帮助钩起组织，从而提高安全性
豪雅集團旗下 PENTAX Medical上市用於胃癌早期治療的 新款多功能內視鏡黏膜下剝離器材Splash M-Knife
東京–(BUSINESS WIRE)–(美國商業資訊)–豪雅集團旗下PENTAX Medical上市新款多功能內視鏡黏膜下剝離器材Splash M-Knife，以實現透過單件器材完成完全性內視鏡黏膜下剝離術（以下簡稱ESD）。該新款器材將在日本消化器內視鏡學會(JGES) 第89屆年會上展示，該年會將於2015年5月29至31日在日本名古屋召開。 開發可彎曲內視鏡旨在與其他治療器材一起用於各類微創治療手術。ESD是十多年前日本發明的一種手術，由於其具有臨床和經濟效益，有助於早期恢復、降低複雜性和成本，因而已在世界各地普及。 全球產品管理副總裁Rami Liebenthal做出如下評論：「我們正在上市Splash M-Knife，這是一種創新的多功能ESD器材，它有助於ESD的全球普及，加快胃癌的早期治療。我們相信，用於精確、高效率、更安全ESD的創新器材為展開完全性ESD治療設立了一個新標準。我們致力於推廣該手術及其進一步的開發。」 Splash M-Knife具有下列特點。 多功能它可實現清晰的標記、更好的止血、更順利更輕鬆的手術，手術過程中無需替換刀具。 獨特的機制刀具中的
Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that the United States Patent and Trademark Office (USPTO) issued three new U.S. Patents, Nos. 9,040,770, 9,040,039 and 9,040,038, which expand the scope of protection of the four previously issued U.S. patents covering its retinal pigment epithelium (RPE) transplant technology. These three new patents extend protection to